New Democrat Coalition Sets 2012 Healthcare Priorities

Margaret Dick Tocknell, for HealthLeaders Media , December 14, 2011

2.Facilitate cooperation between the public and private sectors to promote successful implementation of healthcare delivery models that increase efficiency and improve patient care.

  • Facilitate participation in new Medicare delivery models by allowing successful multi-payer demonstrations to expand to traditional Medicare fee-for-service beneficiaries.
  • Enable private payers to invest in infrastructure development for smaller practices that want to develop or participate in innovative care delivery models.
  • Improve consistency in data collection and analysis across Medicare shared savings programs.
  • Consolidate elements of various shared savings programs such as quality reporting systems and technical assistance to conserve resources.
  • While protecting patient privacy, increase de-identified data sharing across the Medicare program to allow for more accurate comparisons of spending and outcomes.
  • Invest in enhanced research, better care coordination, and disease management through continued support for providers and third-party payers to reduce the burden of ICD-10 conversion.

3.Modernize the FDA approval process to foster innovation, growth through competition, and timely patient access to new treatments and technologies.

  • Ensure that the FDA has the funding and Congressional support to carry out its mission.
  • Ensure that the FDA uses its funding more efficiently to meet its performance targets and keeps a concentrated, top-to-bottom focus on innovation.
  • Engage industry stakeholders to better assess the cost of moving products through the FDA approval process.
  • Build on the successful practices demonstrated through FDA's 510(k) approval process that allow safe and effective technology and innovations to get to market in the most efficient way possible.
  • Address uncertainties in the FDA approval process by setting explicit and transparent guidelines for drug and device manufacturers.
  • Foster an open dialogue between regulators and the private sector to reduce administrative burdens on both sides.
1 | 2 | 3 | 4

Comments are moderated. Please be patient.




FREE e-Newsletters Join the Council Subscribe to HL magazine


100 Winners Circle Suite 300
Brentwood, TN 37027


About | Advertise | Terms of Use | Privacy Policy | Reprints/Permissions | Contact
© HealthLeaders Media 2015 a division of BLR All rights reserved.